MAPK3 and gastric cancer: Moreover, bortezomib reduced phosphorylation of ERK1/2, but improved JNK phosphorylation, and also bortezomib-mediated DR5 upregulation was blocked only by suppressing activation of ERK1/2 but not JNK in gastric cancer cells (94).